How Hormones and Exposure and Response Prevention (EX/RP) Affect the Brain of People With OCD

Официальное название

Harnessing Hormonal Variation to Probe Neural Mechanisms and Optimize CBT Outcomes for OCD

Обзор

Studies show that hormones affect the brain's fear extinction network, which is relevant for therapy involving exposure and response prevention (EX/RP), a first-line treatment for obsessive compulsive disorder (OCD). This study will examine the effect of delivering EX/RP to women during different phases in their menstrual cycle to determine the effects of hormones on the fear extinction network and on their OCD symptoms.

Подробное описание

This study involves neuroimaging and a brief EX/RP protocol. The investigators will recruit both male and female participants. All participants will complete neuroimaging, hormonal assays and symptom ratings before and after a brief course of EX/RP. Female participants will be randomized to complete brief EX/RP during distinct phases of their menstrual cycles. This design will allow the investigators to study the effects of hormonal variation during the menstrual cycle and sex on the fear extinction network and on EX/RP outcome. The long-term goal is to optimize EX/RP for individuals suffering from OCD. Men will also be recruited for this study to further explore biological sex differences. The results will elucidate treatment mechanisms and could lead to personalized treatment recommendations for women with OCD.

Вмешательства

• Поведенческое Exposure & Response Prevention (EX/RP)
  Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD. This is a brief protocol consisting of 8 sessions of exposure and Response Prevention (EX/RP). This protocol includes two psychoeducation/planning sessions, followed by six exposure sessions.

Первичные конечные точки

• fMRI [Срок оценки: Baseline to approximately 4 weeks later]
• OCD Symptoms [Срок оценки: Baseline to approximately 4 weeks later]

Вторичные конечные точки (1)

• rs fMRI [Срок оценки: Baseline to approximately 4 weeks later]

Критерии участия

Критерии включения

• Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Diagnosis of OCD;
• Male and female subjects aged between 18- 45;
• Women must be menstruating and regularly cycling
• Ability to tolerate a treatment-free period;
• No psychotropic medication in the past 12 weeks
• At entry, at least moderate severity OCD
• Willingness and ability to give written informed consent after full explanation of study procedures.

Критерии исключения

• Use of birth control (oral contraception or IUD) that affects the menstrual cycle, or menopause.
• Pregnancy. Women of childbearing potential will be required to sign a statement indicating their intention to avoid pregnancy during the study.
• Neurologic or medical condition that would prevent safe participation in the full study protocol.
• Any contradiction to magnetic resonance imaging (e.g., metallic implants or devices).
• Comorbid psychiatric conditions that significantly elevate the risks associated with study participation or confound results.
• Patients with prominent suicidal ideation or with a recent suicide attempt.
• Current psychotherapy

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

США · 2 центра

• New York State Psychiatric Institute — New York
• University of Pennsylvania — Philadelphia

Идентификаторы

NCT: NCT05359562 · 1R01MH121608-01A1 · 1R01MH121597-01A1

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗